Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) CEO Sells $238,396.99 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $238,396.99. Following the transaction, the chief executive officer now owns 491,329 shares of the company’s stock, valued at $1,213,582.63. The trade was a 16.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Fractyl Health Price Performance

NASDAQ GUTS opened at $1.97 on Friday. Fractyl Health, Inc. has a one year low of $1.74 and a one year high of $14.50. The stock has a 50-day moving average of $2.58 and a 200 day moving average of $4.03. The company has a market capitalization of $94.52 million and a price-to-earnings ratio of -0.16. The company has a debt-to-equity ratio of 0.60, a quick ratio of 7.46 and a current ratio of 5.58.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. The firm had revenue of $0.01 million during the quarter. On average, sell-side analysts forecast that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Institutional Trading of Fractyl Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in GUTS. American International Group Inc. bought a new stake in Fractyl Health during the 1st quarter valued at approximately $9,911,000. M28 Capital Management LP bought a new stake in Fractyl Health during the 1st quarter valued at approximately $13,735,000. Rhumbline Advisers bought a new stake in Fractyl Health during the 2nd quarter valued at approximately $32,000. Massachusetts Financial Services Co. MA increased its stake in Fractyl Health by 2.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock worth $4,255,000 after acquiring an additional 25,829 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Fractyl Health in the 2nd quarter worth approximately $61,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.